Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of ....

AMERISE BIOSCIENCES LIMITED CIN: L29199GJ1984PLC007195 (Formerly Known as AMRADEEP INDUSTRIES LIMITED) Date: 03.08.2026 Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Dear Sir / Madam, Scrip Code: 531681 Security ID: AMERISE Subject: Outcome of Board Meeting held on 3rd August 2026. Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Monday 3rd August,2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2026. The board meeting commented at 04:50 PM and concluded at 05:10 PM Please take the above intimation in your records. Thanking You, Yours Faithfully, For, Amerise Biosciences Limited ALBERT HINES Whole-time Director DIN: 10742692 REG. OFFICE: 24, LAXMI CHAMBERS, NAVJEEVAN PRESS ROAD, OPP. OLD GUJARAT HIGH CORT, AHMEDABAD-380014. E Mail: amradeepindustries@gmail.com Amerise Biosciences Ltd CIN:- L29199GJ1984PLC007195 Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014 Email:- amradeepindustries@gmail.com (Rs. In lacs) Statement of Un-audited Standalone Financial Results for the Quarter Ended June 30, 2026 Quarter Ended Year Ended Sl no. Particulars 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 (Refer Notes Below) (Unaudited) (Audited) (Unaudited) (Audited) INCOME (a) Gross Revenue from sale of products - - - - (b) Other Operating Revenue - 7.92 6.37 25.52 1 Revenue from Operations - 7.92 6.37 25.52 2 Other Income - - - - 3 Total Income - 7.92 6.37 25.52 EXPENSES (a) Cost of materials consumed - - - - (b) Purchases of Stock-in-Trade - (c) Changes in inventories of finished goods, work-in-progress, - - - - and stock-in-trade (d) Employee benefit expense 0.94 1.45 2.32 7 .37 (e) Finance Costs - - - - (f) Depreciation and amortization expense - - - - (g) Other expenses 7.21 0.34 4.86 1 6.09 4 Total Expenses 8.14 1.79 7.18 2 3.46 5 Profit / (Loss) from operations before exceptional items (8.14) 6.13 (0.81) 2 .06 Tax (1-2) 6 Exceptional Items - - - - 7 Profit / (Loss) before Tax (5 ± 6) (8.14) 6.13 (0.81) 2 .06 8 Tax Expense - - - 0.45 9 Net Profit / (Loss) after Tax (7 - 8) (8.14) 6.13 (0.81) 1 .61 10 Other Comprehensive Income (net of tax ) - - - - (i) Items that will not be reclassified to profit or loss - - - - A (ii) Income tax relating to items that will not be reclassified to - - - - profit or loss (i) Items that will be reclassified to profit or loss - - - - B (ii) Income tax relating to items that will be reclassified to - - - - profit or loss Total Comprehensive Income for the period (9 ± 10) (8.14) 6.13 (0.81) 1 .61 12 Paid-up equity share capital (Face Value of Rs.1/- each) 660.69 660.69 660.69 6 60.69 13 Other Equity - - - ( 121.10) 14 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic (0.01) 0.01 (0.00) 0 .00 (b) Diluted (0.01) 0.01 (0.00) 0 .00 Notes: 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 03, 2026. The Statutory Auditors have carried out a limited review of the above financial result. 2 Company has only one segment and hence no separate segment result has been given. 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary. 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Amerise Biosciences Ltd Albert Hines Place : Ahmedabad Wholetime Director Date : 03rd August, 2026 DIN: 10742692 BIPIN & Co. CAr TEJAS PUROHIT F.CA, DISA. M. Com. 98257 68699 CAr DHARIT K. SHAH F.CA, Ll.B., B. Com. 94273 41134 CA. AMIT D. SHAH F.CA. . D.T.P., B. Com. 94.263 13900 CitARTEREd ACCOUNTANTS CAr SURESH SISODIA F.CA, A.C.S., Ll.B. 98251 56037 C' FlIIiR" ns .'1'1nZIA PS?Z? INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF STANDALONE FINANCIAL RESULTS To the Board of Directors of Amerise Blosclences Ltd 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Amerise Biosciences Ltd ("the Company") for the quarter ended 30 June 2026 ("the Statement"), being submitted pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 .read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial In/ormation Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (lCAI). This standard requires that we plan and perform the review to obtailllm.qderate assurance as to whether the Statements are free of material misstatement. A'~evi~W of interim financial infonnation consists of making inquiries, primarily of persons resPQl1sible for financial and accounting matters, and applying analytical and other review pro.C'edures. A review is substantially less in scope than an audit conducted in accordance with Standard of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly; wet-dor not express an audit opinion. I ... ·:) 4. Based on our review conducted as stated in paragraph 3 above, nothing has corrot.lo:our attention that causes us to believe that the Statement has not been prepared in accord-ance with all material respects in accordance with the recognition and measurement--Jprineiples laid down in the aforesaid Indian Accounting Standard and other recognized accounting practices generally accepted in India and has not disclosed the information requjred to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the ·mantler 'in which it is to be disclosed, or that it contains any material misstatement. . ,~ , ! I: ' FOR, BIPIN & CO. CHARTERED ACCOUNTANTS CA .............. r' .. PLACE: VA DARA DATE: 03/08 2026 UDIN: 26126337KNXQIC2263 ,·,1 , -r~r ·r,f· Head Office : 302/301, Centre Point, R. C. Dutt Road, Alkapuri, Vadodara-390007. Ph ..: 02~5-2;3~.8~~5, 3?3577 E-mail: bipin.smdt@gmail.cdm/bipin.co@gmail.com/amit_d_shah@redlffmall.com t, ,